Results of 2026 Annual General Meeting
Released
Released
Announcement PDF
ASX Announcement
Results of 2026 Annual General Meeting
Melbourne, Australia; 6 November 2026: Starpharma (ASX: SPL, US OTC: SPHRY), today announces
the details of the resolutions and the proxies and votes received in respect of each resolution at its
Annual General Meeting (AGM), held today in accordance with ASX Listing Rule 3.13.2 and section
251AA of the Corporations Act, as set out in the appended proxy and voting summary.
About Starpharma
Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing
dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve
improved health outcomes and quality of life through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure,
high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets,
preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
Investor & Media Relations
Gabriella Hold
gaby@thecapitalnetwork.com.au
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations
Officer and Company Secretary
+61 3 8532 2700
investor.relations@starpharma.com
Level 3, 40 River Boulevard
Richmond VIC 3121
Disclosure
This ASX Announcement
was authorised for release
by the Chair, Dr Russell
Basser.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s
and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be
approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding
the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain
patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and
additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or
developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not
necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or
reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.
Resolution
Result
Resolution
Resolution
Type
For Against
Proxy's
Discretion
Abstain For Abstain*
Carried /
Not Carried
141,233,988 7,737,207 514,752 592,193 147,111,433 592,193 Carried
94.48% 5.18% 0.34% 94.84%
83,963,341 69,769,539 514,752 152,635 90,959,290 160,235 Carried
54.43% 45.23% 0.34% 56.57%
153,496,464 167,566 583,602 152,635 160,612,342 152,635 Carried
99.51% 0.11% 0.38% 99.88%
153,594,482 170,066 514,752 120,967 160,671,510 120,967 Carried
99.55% 0.11% 0.34% 99.89%
147,229,696 1,645,870 514,752 687,822 153,107,141 687,822 Carried
98.56% 1.10% 0.34% 98.77%
140,980,696 8,402,471 514,752 180,221 146,761,119 180,221 Carried
94.05% 5.61% 0.34% 94.37%
6 Approval of issue of Performance
Rights to Ms Cheryl Maley
Ordinary
8,758,184
5.63%
* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
4 Re-Election of Dr Russell Basser Ordinary
171,756
0.11%
5 Approval of Starpharma Holdings
Limited Performance Rights Plan
Ordinary
1,904,561
1.23%
2 Re-Election of Mr Robert B Thomas
AO
Ordinary
69,844,708
43.43%
3 Re-Election of Mr David McIntyre Ordinary
199,256
0.12%
Against
1 Adoption of Remuneration Report Ordinary
7,995,898
5.16%
Resolution details Instructions given to validly appointed proxies Number of votes cast on the poll
(as at proxy close) (where applicable)
Starpharma Holdings Limited
Annual General Meeting
Friday, 6 November 2026
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
1/1
Share your feedback
Discover